广东信达律师事务所 股东会法律意见书 中国深圳福田区益田路 6001 号太平金融大厦 11 楼、12 楼 邮政编码：518038 11、12/F, TaiPingFiance Tower,Yitian Road 6001,Futian District, ShenZhen, P. R. China 电话(Tel.)：(0755) 88265288 传真(Fax.)：(0755)88265537 网址(Website)：https://www.sundiallawfirm.com 广东信达律师事务所 关于仙乐健康科技股份有限公司 2026年第二次临时股东会的 法律意见书 信达会字（2026）第033号 致：仙乐健康科技股份有限公司（下称"贵公司"） 广东信达律师事务所接受贵公司的委托，指派周蒴婷律师及高灵灵律师（下 称"本所律师"）参加了贵公司2026年第二次临时股东会（下称"本次股东会"）， 并进行了必要的验证工作。现根据《中华人民共和国公司法》（下称"《公司法》"）、 《上市公司股东会规则》（下称"《股东会规则》"）、《深圳证券交易所上市 公司股东会网络投票实施细则》（下称"《网络投票实施细则》"）等法律法 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2026-027 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 2026 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现增加、否决或变更议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、 会议召开情况 1、现场会议召开时间：2026 年 2 月 26 日（星期四）下午 15:00 2、现场会议召开地点：上海市青浦区赵巷镇佳杰路 99 弄 2 号 8 层会议室， 公司现场会议同时提供了远程视频参会系统。 3、网络投票时间：2026 年 2 月 26 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 2 月 26 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 其中：通过现场投票的股东 9 人，代表股份 194,969,314 股，占公司有表决 权股份总数的 63.6429%。 通过深 ...

此外，仙乐健康的资产质量正面临严峻挑战。招股书显示，截至2025年9月30日，公司流动净资产由2024年末的11.98亿元骤降56.8%至5.17亿元，半年多 时间缩水超6亿元。这一滑坡主要源于其他金融负债增加4.56亿元、贸易应付款项增加1.58亿元、借款增加0.95亿元，同时现金及现金等价物减少0.97亿 元，资金链紧张态势凸显，以及公司短期偿债能力的显著下降。 | | 截至12月31日 | | 截至9月30日 | | --- | --- | --- | --- | | | 2023年 | 2024年 | 2025年 | | | | (人民幣千元) | | | | | | (未經審核) | | 流動資產總值 | 1,932,928 | 2,022,938 | 2,156,451 | | 非流動資產總值 | 3,262,799 | 3,463,084 | 3,525,715 | | 資產總值 | 5,195,727 | 5,486,022 | 5,682,166 | | 流動負債總額 . | 751.129 | 824.537 | 1.639.225 | | 非流動負債總額 .. | 1.878.430 | ...

中国经济网北京2月25日讯仙乐健康（300791）(300791.SZ)日前发布的2025年度业绩预告显示，预计 2025年归属于上市公司股东的净利润10,124.16万元至15,135.61万元，比上年同期下降53%至69%；归属 于上市公司股东的扣除非经常性损益的净利润5,750.28万元至8,596.67万元，比上年同期下降74%至 82%。 仙乐健康2019年9月25日在深交所创业板上市，本次发行股份数量为2,000万股，全部为公开发行新股， 不安排老股转让，本次发行价格为54.73元/股。仙乐健康的保荐机构(主承销商)是招商证券股份有限公 司，保荐代表人是谭国泰、黄华。 仙乐健康2019年9月10日发布的首次公开发行股票并在创业板上市招股说明书显示，公司拟募集资金 101,902.23万元，分别用于安徽马鞍山生产基地建设项目、仙乐健康研发中心建设项目、仙乐健康B2B 营销项目、包装车间技术改造项目、偿还银行贷款、补充流动资金。 仙乐健康2021年5月12日发布的向不特定对象发行可转换公司债券上市公告书显示，本次发行可转换公 司债券募集资金总额为1,024,892,900.00元(含发行费用)，募集资 ...

Strategic Advancement - The company has outlined a strategic roadmap for 2026-2028, aiming to become an innovative leader in the nutrition and health sector and the first choice for customers [1] - Plans for an H-share listing are underway, which, if successful, will help address long-term funding needs and advance internationalization strategies [1] Company Status - The company plans to divest its continuously loss-making BF personal care business, expected to be completed within 2026, to recover some capital and avoid non-core business dragging down overall performance [2] Business and Technology Development - The company is accelerating its digital transformation, including the application of technologies such as AI formula engines and data platforms, focusing on AI-driven precision nutrition (e.g., pilot of JsRight app) and pet business to cultivate new long-term growth drivers [3]

Core Viewpoint - Xianle Health has submitted an application for listing on the Hong Kong Stock Exchange, but is facing significant challenges due to the divestment of its personal care business, leading to a projected decline in net profit for 2025 by 53% to 69% compared to 2024 [2][3][14]. Financial Performance - The projected net profit for Xianle Health in 2025 is estimated to be between 101 million and 151 million RMB, a significant drop from 325 million RMB in 2024, indicating a year-on-year decline of 53% to 69% [3][14]. - The non-recurring net profit is expected to fall by over 70%, with estimates ranging from 57.5 million to 85.9 million RMB, reflecting a decline of 74% to 82% [3][14]. - The company reported a revenue of 3.58 billion RMB in 2023, with a projected increase to 4.21 billion RMB in 2024, but a decrease to 3.29 billion RMB in 2025 [4][16]. Business Model and Market Position - Xianle Health operates primarily in the B2B sector, providing comprehensive solutions for global nutrition and health brands, with a focus on soft capsules and gummies as its core high-growth products [2][14]. - The company ranks third in the global nutrition and health food CDMO market and first in the Chinese market based on 2024 revenue [2][14]. Market Trends - There is a notable shift in Xianle Health's business dynamics, with domestic revenue declining while overseas revenue is increasing. In 2024, overseas revenue reached 2.27 billion RMB, a 44.3% increase, accounting for 53.92% of total revenue [5][17]. - Domestic revenue decreased from 2.01 billion RMB in 2023 to 1.94 billion RMB in 2024, a decline of 8.3%, with further decline expected in 2025 [5][17]. Strategic Initiatives - The company is undergoing a transformation, including the divestment of its personal care business and the establishment of a new production base in Thailand [8][20]. - Xianle Health has launched an equity incentive plan, setting ambitious profit targets for 2026 and 2027, aiming for a net profit of no less than 380 million RMB in 2026 and 450 million RMB in 2027 [21][22]. Risks and Challenges - The reliance on foreign currency transactions poses a risk, as fluctuations in exchange rates could significantly impact profits, with financial costs projected to reach 80 million RMB in 2024 [21]. - The company’s core products are dependent on raw materials like gelatin and fish oil, making it vulnerable to price increases, especially as new consumer clients gain bargaining power [21].

Core Viewpoint - Xianle Health announced that its convertible bond "Xianle Convertible Bond" has a current conversion price of 31.86 yuan per share, and the stock price has been below 85% of this conversion price for 10 trading days, indicating a potential downward adjustment condition [2] Group 1 - The stock price threshold for triggering downward adjustment is set at 27.08 yuan per share, which is 85% of the conversion price [2] - The company plans to hold a board meeting to review the adjustment if the condition is triggered, with results to be disclosed before the next trading day [2]

关于仙乐转债预计触发转股价格修正条件的提示性公告 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2026-026 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300791 证券简称：仙乐健康 1 万元。本次向不特定对象发行的可转换公司债券向公司在股权登记日收市后登记 在册的原股东优先配售，原股东优先配售后余额部分（含原股东放弃优先配售部 分）通过深圳证券交易所（以下简称"深交所"）交易系统网上向社会公众投资 者发行，认购金额不足 102,489.29 万元的部分由主承销商余额包销。 （二）可转换公司债券上市情况 2、债券代码：123113 债券简称：仙乐转债 3、转股价格：31.86 元/股 4、转股期限：2021 年 10 月 25 日至 2027 年 4 月 18 日 5、自 2026 年 2 月 2 日至 2026 年 2 月 13 日，公司股票已有 10 个交易日的 收盘价低 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"、"本公司"）于 2026 年 1 月 30 日披露了《关于召开 2026 年第二次临时股东会的通知》（公告编码： 2026-017），公司定于 2026 年 2 月 26 日（星期四）召开 2026 年第二次临时股东 会。为进一步保护投资者的合法权益，方便公司股东行使股东会表决权，现就本 次会议有关事项提示如下： 仙乐健康科技股份有限公司 关于召开 2026 年第二次临时股东会的提示性公告 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2026-025 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 一、召开会议的基本情况 1、股东会届次：2026 年第二次临时股东会 2、股东会的召集人：董事会 3、经公司第四届董事会第十八次会议审议并通过了《关于提请召开 2026 年第二次临时股东会的议案》。本次会议的召集、召开符合《中华人民共和国公 司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 ...

Core Viewpoint - Xianle Health (300791) announced the total guarantee amount provided to its controlling subsidiaries is 348.475 million yuan, with a remaining balance of 128.2388 million yuan, accounting for 5.12% of the latest audited equity attributable to the parent company [1] Group 1 - As of the announcement date, the total guarantee amount provided by the company to its controlling subsidiaries is 348.475 million yuan, with a balance of 128.2388 million yuan [1] - The guarantees provided by the company's controlling subsidiaries to other subsidiaries total 74.8435 million yuan, with a remaining balance of 46.7855 million yuan, representing 1.87% of the latest audited equity attributable to the parent company [1] - The company and its subsidiaries have no overdue external guarantees, nor are there any external guarantees involved in litigation or resulting in losses due to adverse judgments [1]